Related Experiment Video
Updated: Jul 12, 2026
10:41
A Tuberculosis Molecular Bacterial Load Assay (TB-MBLA)
Published on: April 30, 2020
Limited Access to Blinatumomab in Morocco: Challenges and Implications
Nabiha El Abdi1,2, Yasmine El Ouafa2,1, Fatima Azzahra Lahlou3
1Interdisciplinary Laboratory of Biothechnology and Health, Mohammed VI University of Health Sciences (UM6SS), Casablanca, MAR.
Cureus
|July 10, 2026
Summary
Immunotherapy, like blinatumomab, offers improved outcomes for acute lymphoblastic leukemia (ALL). However, access to these advanced treatments remains limited in Morocco due to financial and regulatory barriers, hindering equitable care.
Area of Science:
- Hematology
- Immunotherapy
- Oncology
Background:
- Recent advances in hematology, particularly immunotherapy, have significantly improved outcomes in acute lymphoblastic leukemia (ALL).
- Blinatumomab, a CD19-directed bispecific T-cell engager, has demonstrated substantial efficacy in relapsed or refractory B-cell ALL, achieving high rates of minimal residual disease negativity and improving overall survival.
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:11Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.